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OBJECTIVES: To 1) Determine 2012 price trends for 12 therapeutic areas in 12 
countries; 2) segment countries and therapeutic areas by predominant price 
trend, and 3) analyse drivers behind price movements. METHODS: We analysed 
price movements over 2011-2012 for oncologics (L01, L02), respiratory products 
(R03), antidiabetics (A10A, A10B), lipid regulators (C10A, C10C, C11), 
antipsychotics (N05A), angiotensin II antagonists (C09C, C09D, C09X), anti-
ulcerants (A02B), antidepressants (N06A), antivirals (J05A), platelet aggregation 
inhibitors (B01A), vaccines (J07), and multiple sclerosis treatments in Australia, 
Brazil, Canada, France, Germany, Greece, Italy, Japan, Spain, Turkey, the UK, and 
the United States, using IHS’s pricing database, PharmOnline International. All 
56,949 analysed presentations were studied for their 2012 price trend (“price cut”, 
“price increase”, and “no price change”). Within each country, therapeutic areas 
were assigned a predominant price trend on a percentage basis. RESULTS: In 
2012, four markets (France, Italy, UK, United States) were associated with price 
stability as a predominant price trend across the therapeutic areas considered 
while five (Australia, Canada, Greece, Japan Turkey) were associated with price 
cuts, one (Germany) with price increases and two (Brazil, Spain) with co-
dominant price trends. In 2012, six therapeutic areas (L01/L02, R03, A10A/A10B, 
J05A, B01A, and J07) were associated with price stability as a predominant price 
trend across the markets considered while six (C10A/C10C/C11, N05A, 
C09C/C09D/C09X, A02B, N06A, multiple sclerosis treatments) were associated 
with price cuts. CONCLUSIONS: Price trends vary not only by country and 
therapeutic area but also over time. At the country level, predominant price 
trends reflect the role that national P&R systems and pricing policy play as 
drivers of price changes. At the therapy area level, dominant pricing trends 
somewhat correlate with the extent of generic competition.  
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OBJECTIVES: To study the quality of patients' drug supply within the framework 
of the guaranteed volume of free medical care in regions of Kazakhstan. 
METHODS: Anonymous interview of doctors was conducted using a specially 
designed questionnaire comprising 20 questions. Questionnaire survey covered 
638 physicians of medical institutions of Almaty and the five regions of 
Kazakhstan. The analysis was conducted in the outpatient organizations, 
hospitals and health care organizations that provide specialized care. Their 
share of the general sample was 57.4%, 40.8% and 4.9%. RESULTS: The survey 
revealed that 51.7% of the doctors in the interview are directly involved in the 
process of forming the list of drugs to be purchased and knows formulary list of 
medical organization and working with it. 88.9% of respondents have never had 
courses of drug management. In the most cases (70%) sources of information 
about new drugs for doctors are scientific seminars and conferences organized 
by pharmaceutical companies, specialized publications (60%), work colleagues 
and medical representatives (61%), 25% of cases from information materials in 
pharmacies, advertising in media (19%) and specialized exhibitions (15%). 92.7% 
of respondents are rely to a treatment protocols prescribing drugs. At the same 
time, 84.6% of doctors still had to advise patient to buy drugs what don't 
included into formulary list of medical organization for effective treatment. Less 
than 20% of respondents mind about a price of assigned medicine, and only 5% is 
guided by consultation with a pharmacologist. 66.8% of respondents are not 
satisfied or partly satisfied by the quality of purchased drugs. At the same time 
more than 50% reported the absence of efficiency in their prescribing. 
CONCLUSIONS: Thus, there are certain problems in questions of populations’ 
drug supply and also the prescribing and using of medicines by the doctors that 
can affect on the efficiency of the treatment.  
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OBJECTIVES: Title IX of the 2007 Food and Drug Administration (FDA) 
Amendments Act provided the FDA with enhanced authority to ensure drug 
safety by (1) requiring post-approval risk studies; (2) requiring that new safety 
information be added to product labeling; and/or (3) requiring companies to 
submit a Risk Evaluation & Mitigation Strategy (REMS) to ensure that the 
product’s benefits outweighed the risks. The objective of this study was to 
describe national utilization trends for selected drugs for which a REMS has been 
implemented. METHODS: Data were obtained and combined for five years, 2006 
through 2010, from two large national surveys: the National Ambulatory Medical 
Care Survey (NAMCS) and the National Hospital Ambulatory Medical Care Survey 
(NHAMCS). The weighted annual frequencies of drug mentions were computed 
for the following 12 drugs: rosiglitazone, exenatide, olanzapine, quetiapine, 
metoclopraminde, ciprofloxacin, levofloxacin, moxifloxacin, pregamblin, 
topiramate, lamotrigine, and levetiracetam. Each drug had a REMS requirement 
imposed between December 2008 and December 2009. RESULTS: To date there 
have been 206 REMS plans deemed necessary and approved by the FDA, 
including currently active individual and group REMS plans as well as inactive 
(released) REMS programs. In 2006, for the 12 individual drugs selected for this 
study, the number of times a drug was mentioned ranged from 1.1 million for 
exenatide to 6.8 million and 6.9 million for levofloxacin and ciprofloxacin, 
respectively. In the year of REMS approval and/or the year immediately following 
approval, a decline in utilization was observed for 11 of the 12 drugs ranging 
from 4.6% to 53.3% (% change relative to previous year). Only one drug, 
levetiracetam, showed no decline in utilization. CONCLUSIONS: This study 
showed a relationship between REMS implementation and declining utilization. 
However, future work is warranted to evaluate the partial effect of REMS 
implementation compared to other possible factors affecting utilization.  
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OBJECTIVES: One criticism of prescription drug monitoring programs (PDMPs) is 
that they may compromise access to appropriate therapy, called the ‘chilling 
effect’. Previous research evaluating the impact of benzodiazepine monitoring in 
New York (NY) reported that benzodiazepine use dramatically decreased and 
remained stable at that lower level. In January of 2008, South Carolina (SC) 
implemented a PDMP that included benzodiazepine monitoring. We examine the 
impact of the PDMP on benzodiazepine use by comparing use before and after 
implementation. METHODS: We used a publically available, private insurance 
claims database containing records from January 2007 to December 2009. 
Continuously eligible SC residents between ages 19-65 were analyzed. Logistic 
regression models examined the likelihood of filling a benzodiazepine 
prescription during each month. Control variables included PDMP status (active 
vs. inactive) and recipient characteristics (age, gender, race, and education). 
Interaction terms were included to determine if the PDMP had a differential 
impact based on demographics. Statistical analysis was conducted in STATA 
v12.0. RESULTS: A total of 20,260 recipients were included. Regression results 
showed recipients have higher odds of filling a benzodiazepine prescription 
when the PDMP is active versus inactive (p-value<0.001; CI 1.377-2.023). PDMP 
implementation was shown to more negatively impact the likelihood of females 
filling a benzodiazepine prescription compared to males (p-value 0.009; CI 
0.8272-0.9727) and recipients between 50-65 years compared to recipients 19-29 
(p-value 0.034; CI 0.7029 -0.9866). CONCLUSIONS: In this population, the 
implementation of the PDMP did not create a ‘chilling effect’ by decreasing the 
likelihood recipients would fill a benzodiazepine prescription; a contrast to 
previous findings from NY. Our study is limited by the use of a pre/post design 
with only three years of data from a privately insured population. Further 
research should focus on additional states and populations to better determine 
the impact of PDMPs on benzodiazepine use.  
 
PHP27  
REGIONAL VARIATION IN USE OF GENERIC DRUGS AND MEDICARE 
PRESCRIPTION DRUG COST SHARING  
Tang Y1, Gellad WF2, Men A1, Donohue JM1 
1University of Pittsburgh, Pittsburgh, PA, USA, 2VA Pittsburgh Health Care System, RAND, and 
University of Pittsburgh, pittsburgh, PA, USA  
OBJECTIVES: Regional variation in Medicare prescription drug spending is largely 
driven by the use of expensive brand-name drugs versus cheaper generic drugs 
in some areas. We examined the relationship between Part D cost sharing and 
regional variation in use of generic drugs overall and in a widely used drug class: 
statins. METHODS: Data were from a 10% random sample of Medicare 
beneficiaries in 2009. We assigned beneficiaries to 306 hospital-referral regions 
(HRRs). Our outcome measures, constructed at the HRR-level, were the share of 
prescriptions filled for generic drugs, overall and for statins. Key independent 
variables were the absolute dollar difference for the mean copayment between a 
brand-name drug and a generic drug (standardized to a 30-day supply). All 
estimates were adjusted for the demographic and health status differences. 
Spatial lag models were used for estimation in order to account for spatial 
autocorrelation of HRR-level. RESULTS: The share of all prescriptions filled for 
generic drugs ranged across HRRs from 59.1% to 80.3% for drugs overall, and 
from 43.8% to 84.2% for statins. The copayment difference between brand-name 
and generic drugs ranged from $28.9 to $58.0 for drugs overall and from $28.0 to 
$33.7 for statins. Controlling for all other covariates, the copayment difference 
had a strong positive association with share of prescriptions filled for generic 
drugs overall (coefficient: 0.19; p<0.05) and for statins (coefficient: 0.81; p<0.01). 
CONCLUSIONS: Regions with Part D plans that had a larger differential in cost-
sharing between generic and brand-name drugs had higher rates of generic drug 
use than regions where plans had smaller cost-sharing differences. Increasing 
the cost-sharing difference between generic and brand-name drugs could be an 
effective way to encourage greater use of less-expensive generic drugs in high-
cost regions. This change in benefit design could generate substantial savings for 
the Medicare program and for beneficiaries.  
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OBJECTIVES: Imaging diagnostics include test applications in which images of 
living tissue are captured and evaluated for guiding clinical decision-making. In 
recent years, the push for faster, less invasive testing methods has driven the 
rise in development of novel imaging diagnostics for detecting, staging and 
monitoring disease. Imaging diagnostic applications, however, present with 
